Piscataway, NJ - In
an effort to assist their customers, and potential customers,
to understand the scope of Patent # 5,804,596, Sabinsa
Corporation requested its legal counsel, of one of Washington
D.C.'s leading patent and trademark law firms, to review
the claims specified in Patent 596 and give their legal
opinion.
Because Sabinsa discovered
the weight loss properties of forskohlin, which is not
a traditional usage of the herb, they were granted a
patent for its use and composition in promotion of lean
body mass, reduction of adipose tissue (fat) and weight
loss. ForsLean® has
a similar mechanism of action to ephedrine (Ma Haung),
but without the adrenal impact which may be contraindicated
in some cases.
After examining each
of the 8 patent claims made, their conclusion is that "we believe that claims
1-8 of 596 Patent would be interpreted by a court to encompass
the administration of forskohlin (forskolin) as a dietary
supplement to an individual to promote lean body mass and
shift the proportion of lean body mass and adipose tissue
in favor of lean body mass so as to provide an increase
in lean body mass, a reduction in adipose tissue and weight
loss".
The language is very
specific in the patent regarding "the use of forskohlin
(forskolin) as a 'dietary
supplement' for the 'dietary purposes of promoting lean
body mass or shifting the proportion of mass in favor of
lean body mass.'. Additionally, "...the prosecution history
further supports the interpretation that claims 1-8 encompass
the administration of forskohlin (forskolin) so as to provide
for the reduction of adipose tissue and weight loss in
an individual." The patent also covers a therapeutic dosage
range for forskohlin (forskolin) based on two preliminary
clinical trials exclusively involving the company's ForsLean® ingredient.
Based on this intellectual
property, the application and use of ForsLean® , for
dietary purposes in weight loss, promotion or enhancement
of lean body mass, and reduction of body fat is plainly
defined in US Patent #5,804,596.
Sabinsa intends to make the use of these
claims, along with the use of the patent number, available
to dietary supplement manufacturers and marketers through
a non-exclusive licensing agreement.
For more information
please check the ForsLean® web site at www.forslean.com
, or ww.forslean.net contact Sabinsa at either the New Jersey
office (732-777-1111) or the Utah office (801-465-8400).
ForsLean® is a registered trademark
of Sabinsa Corporation